Library / regulatory-reference
Iraq: General Company for Marketing Medicines and Medical Supplies (KIMADIA)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national structure
Medicines oversight in Iraq sits with the Ministry of Health, and the General Company for Marketing Medicines and Medical Supplies, known as KIMADIA, is the ministry's state company for procuring and distributing medicines and medical supplies to the public health system.
Because the public system dominates medicine supply in Iraq, the company's registration, tendering and import decisions shape which products reach most patients in the country.
How products enter the market
Medicines must be registered with the health authorities before marketing, with documentation on quality, safety and manufacturing practice reviewed through the ministry's technical processes. Importation for the public sector runs through the state company's tender and contracting channels.
Post-market supervision, quality testing and recall decisions rest with the health ministry's inspection and laboratory functions.
Regional and international role
Iraq is a significant medicines import market in the Middle East, and its reliance on imported products makes its registration and procurement rules important for manufacturers seeking regional entry.
Reconstruction of domestic regulatory capacity has been an ongoing theme, with regional cooperation on quality assurance and supply-chain security.
Using this profile
The state company publishes tenders, announcements and product information in Arabic through its official portal, which is the primary source for current procedures and listed in this profile's internal reference record.
For cross-country comparison: Iraq illustrates the state-procurement-anchored system: a ministry regulator paired with a powerful state importing company, where market access runs through public tendering as much as through registration.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.